FibroBiologics faces Nasdaq delisting after shares close below $1 for 30 consecutive business days
HOUSTON, July 24. Thirty consecutive business days with closing bid prices below $1.00 per share triggered a Nasdaq Staff Determination letter to FibroBiologics, Inc. (Nasdaq: FBLG) on July 22, 2026, notifying the Houston-based company that its securities are scheduled for removal from The Nasdaq Capital Market. The noncompliant period ran from June 8 through July 21, breaching Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
Key takeaways
- FibroBiologics received a Nasdaq Staff Determination letter on July 22, 2026, after its shares closed below $1.00 for 30 consecutive business days from June 8 through July 21, breaching Nasdaq Listing Rule 5550(a)(2).
- The company forfeits the standard 180-calendar-day cure period under Nasdaq Rule 5810(c)(3)(A)(iv) because it effected a reverse stock split within the prior one-year period.
- Trading in FBLG will be suspended at the opening of business on July 31, 2026, unless FibroBiologics requests a formal appeal by July 29, 2026.
- FibroBiologics intends to submit a timely hearing request to a Nasdaq Hearings Panel, which will stay further delisting action through the hearing process.
- No remediation or compliance plan was attached to the company's 8-K filing.
HOUSTON, July 24. Thirty consecutive business days with closing bid prices below $1.00 per share triggered a Nasdaq Staff Determination letter to FibroBiologics, Inc. (Nasdaq: FBLG) on July 22, 2026, notifying the Houston-based company that its securities are scheduled for removal from The Nasdaq Capital Market. The noncompliant period ran from June 8 through July 21, breaching Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
Reverse stock split forfeits the standard cure period
Most companies that fall below the minimum bid requirement receive a 180-calendar-day window to return to compliance. FibroBiologics does not. The Staff Determination cited Nasdaq Listing Rule 5810(c)(3)(A)(iv), which blocks that grace period for any issuer that has effected a reverse stock split during the prior one-year period. The 8-K, signed by Chief Executive Officer Pete O'Heeron and dated July 24, did not specify the timing or ratio of that prior split.
Suspension timeline and appeal window
If FibroBiologics does not request a formal appeal by July 29, 2026, trading in FBLG will be suspended at the opening of business on July 31. The company disclosed it intends to submit a timely hearing request to a Nasdaq Hearings Panel. Filing that request will stay further delisting action through the hearing process.
At the hearing, FibroBiologics said it plans to present a compliance plan to the Panel. No specifics were disclosed. The company acknowledged in the filing that no assurance exists that the Panel will grant continued listing, or that the company will be able to regain or maintain compliance with any applicable Nasdaq listing standard.
No compliance plan attached to the filing
FibroBiologics, incorporated in Delaware and headquartered at 9350 Kirby Drive, Suite 300 in Houston, Texas, is classified as an emerging growth company under SEC rules. The company said it intends to monitor its common stock's closing bid price and evaluate all available options to return to compliance with the Bid Price Rule. No remediation plan was attached to the 8-K.
Absent a successful appeal, trading suspension is scheduled for the opening of business on July 31, 2026.